<p>Genomic DNA from FFPE tissues were used for AsP and Mult-AsP PCR assay. In all cases the qPCR assays contained the non-mutated reference control reaction (red line). Each DNA was amplified in AsP and Multi-AsP PCR (green and blue lines, respectively). In gray curves indicated NTC reaction.</p
<p><b>A and B</b>: Corresponding tissue section with areas marked for macrodissection containing ∼70...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
Establishing the KRAS mutational status of tumor samples is essential to manage patients with colore...
İstanbul Bilim Üniversitesi, Tıp Fakültesi.The KRAS pathway and studies evaluating KRAS as a prognos...
BACKGROUND:Patients with KRAS mutations do not respond to epidermal growth factor receptor (EGFR) in...
The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor tar...
Background Colorectal cancer patients harbouring KRAS mutations in codon 12 or 13 do not benefit fro...
The high degree of intra-tumor heterogeneity has meant that it is important to develop sensitive and...
Recently, evidence has emerged indicating that assessment of KRAS mutations before anti-epidermal gr...
WOS: 000297263500015PubMed ID: 21699410The KRAS pathway and studies evaluating KRAS as a prognostic ...
Aims: Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS...
Aims: Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
<p><b>A and B</b>: Corresponding tissue section with areas marked for macrodissection containing ∼70...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
Establishing the KRAS mutational status of tumor samples is essential to manage patients with colore...
İstanbul Bilim Üniversitesi, Tıp Fakültesi.The KRAS pathway and studies evaluating KRAS as a prognos...
BACKGROUND:Patients with KRAS mutations do not respond to epidermal growth factor receptor (EGFR) in...
The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor tar...
Background Colorectal cancer patients harbouring KRAS mutations in codon 12 or 13 do not benefit fro...
The high degree of intra-tumor heterogeneity has meant that it is important to develop sensitive and...
Recently, evidence has emerged indicating that assessment of KRAS mutations before anti-epidermal gr...
WOS: 000297263500015PubMed ID: 21699410The KRAS pathway and studies evaluating KRAS as a prognostic ...
Aims: Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS...
Aims: Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
<p><b>A and B</b>: Corresponding tissue section with areas marked for macrodissection containing ∼70...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...
Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorec...